Literature DB >> 24732837

Efficacy of anti-nerve growth factor therapy for discogenic neck pain in rats.

Takeshi Sainoh1, Yoshihiro Sakuma, Masayuki Miyagi, Sumihisa Orita, Kazuyo Yamauchi, Gen Inoue, Hiroto Kamoda, Tetsuhiro Ishikawa, Miyako Suzuki, Go Kubota, Yasuhiro Oikawa, Kazuhide Inage, Jun Sato, Junichi Nakamura, Yasuchika Aoki, Masashi Takaso, Tomoaki Toyone, Kazuhisa Takahashi, Seiji Ohtori.   

Abstract

STUDY
DESIGN: Immunohistological analysis of the cervical dorsal root ganglia (DRG).
OBJECTIVE: To investigate immunohistologically in rats whether intradiscal administration of anti-nerve growth factor (NGF) antibody in injured cervical intervertebral discs (IVDs) suppresses pain-related peptide expression in DRG neurons. SUMMARY OF BACKGROUND DATA: Neck pain can involve the entire neck and become chronic and intractable. Cervical disc degeneration is a primary cause of neck pain, and pain-related mediators, such as NGF, have been correlated with discogenic pain.
METHODS: We examined Sprague-Dawley rats that received 10 punctures in the C5-C6 IVD, and were treated with saline (puncture group) or an anti-NGF antibody (anti-NGF group). The retrograde neurotracer Fluoro-Gold (FG) was then injected into the C5-C6 IVD. In addition, we examined a sham group that did not receive punctures (disc nonpuncture). The C2-C7 DRG were harvested 1 week after surgery and immunostained for calcitonin gene-related peptide (CGRP), a marker for peptide-containing neurons. We determined for each group the percentages of FG-labeled DRG neurons that were CGRP-immunoreactive (CGRP-ir).
RESULTS: FG-labeled neurons innervating the C5-C6 IVD were found in all C2-C7 DRG examined. The percentage of FG-labeled CGRP-ir DRG neurons in the puncture group was significantly higher than that observed in the sham (P < 0.001) and anti-NGF groups (P < 0.001), but there was no significant difference between the sham and anti-NGF groups (P > 0.05). Therefore, intradiscal administration of anti-NGF antibody suppressed CGRP expression the cervical DRG.
CONCLUSION: Neurons located in the C2-C7 DRG innervated the C5-C6 IVD. These findings indicate that neck pain may be derived from degenerated IVDs. Furthermore, intradiscal administration of anti-NGF antibody suppressed CGRP expression in the cervical DRG innervating the injured IVD. Therefore, inhibiting NGF upregulation in the cervical IVD may be an efficient treatment for discogenic neck pain. LEVEL OF EVIDENCE: N/A.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24732837     DOI: 10.1097/BRS.0000000000000340

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  5 in total

1.  Different responses of cervical intervertebral disc caused by low and high virulence bacterial infection: a comparative study in rats.

Authors:  Jie Li; Yilei Chen; Hao Wu; Zhi Shan; Dikai Bei; Kaifeng Gan; Junhui Liu; Xuyang Zhang; Binhui Chen; Jian Chen; Feng-Dong Zhao
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

2.  Development of an in vitro intervertebral disc innervation model to screen neuroinhibitory biomaterials.

Authors:  Sarah M Romereim; Caleb A Johnston; Adan L Redwine; Rebecca A Wachs
Journal:  J Orthop Res       Date:  2019-12-19       Impact factor: 3.494

3.  Efficacy of coblation technology in treating cervical discogenic upper back pain.

Authors:  Liangliang He; Yuanzhang Tang; Xiuliang Li; Na Li; Jiaxiang Ni; Liangliang He
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

4.  Cervical disc degeneration and neck pain.

Authors:  Baogan Peng; Michael J DePalma
Journal:  J Pain Res       Date:  2018-11-14       Impact factor: 3.133

5.  The efficacy of nerve growth factor antibody in a mouse model of neuropathic cancer pain.

Authors:  Masayuki Miyagi; Tetsuhiro Ishikawa; Hiroto Kamoda; Miyako Suzuki; Gen Inoue; Yoshihiro Sakuma; Yasuhiro Oikawa; Kentaro Uchida; Takane Suzuki; Kazuhisa Takahashi; Masashi Takaso; Seiji Ohtori
Journal:  Exp Anim       Date:  2016-05-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.